NIKKEI 225
38,405.66 +470.90 (+1.24%) HANG SENG
17,763.03 +16.12 (+0.09%) CRUDE OIL
81.98 -0.65 (-0.79%) GOLD FUTURES
2,306.90 -50.80 (-2.15%) DOW
37,994.33 -391.76 (-1.02%) Bitcoin GBP
50,119.69 -539.11 (-1.06%)
VRTX Sep 2024 260.000 put
| Previous close | 0.8500 |
| Open | 0.9500 |
| Bid | 0.0000 |
| Ask | 4.7000 |
| Strike | 260.00 |
| Expiry date | 2024-09-20 |
| Day's range | 0.8000 - 0.9500 |
| Contract range | N/A |
| Volume | |
| Open interest | 780 |
ZacksVertex (VRTX) to Report Q1 Earnings: What's in the Cards?
Vertex's (VRTX) revenues in the first quarter of 2024 are likely to have been driven by the robust sales of its lead CF product, Trikafta/Kaftrio.
ZacksVertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?
Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Business WireVertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older
LONDON, April 26, 2024--Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.
